Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_2
6
86%
Ph phase_3
1
14%

Phase Distribution

0

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
6(85.7%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Phase 26 (85.7%)
Phase 31 (14.3%)

Trials by Status

terminated229%
completed571%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_2

Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas

NCT01338857
completedphase_3

Sequential Study to Treat Renal Cell Carcinoma

NCT00732914
completedphase_2

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

NCT00498836
completedphase_2

Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

NCT00922584
terminatedphase_2

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

NCT00607438
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01338857Phase 2

Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas

Terminated
NCT00732914Phase 3

Sequential Study to Treat Renal Cell Carcinoma

Completed
NCT00498836Phase 2

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Completed
NCT00922584Phase 2

Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

Completed
NCT00607438Phase 2

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

Terminated
NCT00887107Phase 2

Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

Completed
NCT00619996Phase 2

Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7